EPISKIN

Executive Summary

EPISKIN SA, founded in 1992 and headquartered in Lyon, France, is a world leader in tissue engineering, specializing in the development and industrialization of reliable, reproducible in vitro 3D human skin and epithelial models. These models serve as alternatives to animal testing for safety and efficacy evaluation of raw materials, active ingredients, and finished products in the cosmetic, pharmaceutical, and chemical industries. With over three decades of expertise, EPISKIN has established a strong reputation for quality and innovation, providing essential tools for regulatory compliance and ethical testing. The company's products, including epidermis, full-thickness skin, and various mucosa models, are widely recognized and adopted globally. Looking forward, EPISKIN is well-positioned to benefit from increasing regulatory pressure to reduce animal testing and growing demand for advanced in vitro models. The company is expected to continue expanding its product portfolio and geographic reach, particularly in Asia where animal testing bans are tightening. Potential catalysts include new model launches, strategic partnerships with major cosmetics and pharmaceutical companies, and regulatory endorsements for its methods. As a private firm, EPISKIN may also attract investment or acquisition interest given its strong market position. Overall, EPISKIN's long track record and alignment with industry trends underpin a positive outlook.

Upcoming Catalysts (preview)

• Q3 2026Launch of Next-Generation Full-Thickness Skin Model with Immune Cells70% success
• TBDMajor Partnership with Top-5 Cosmetics Company for Global Safety Testing60% success
• Q3 2026Regulatory Approval for Skin Model as OECD Test Guideline for Eye Irritation50% success